Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 17/20 | 1.00 |
| ▸ | S1PR3 | Q99500 | 14/20 | 1.00 |
| ▸ | S1PR4 | O95977 | 5/20 | 1.00 |
| ▸ | S1PR5 | Q9H228 | 4/20 | 1.00 |
| ▸ | S1PR2 | O95136 | 3/20 | 1.00 |
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.70 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.70 |
| ▸ | TNNC1 | P63316 | 2/20 | 0.68 |
| ▸ | SGPL1 | O95470 | 1/20 | 0.68 |
| ▸ | GPR183 | P32249 | 1/20 | 0.68 |
| ▸ | CERS2 | Q96G23 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fty720-P SCHEMBL1497894 | 1.00 | S1PR1 (1.00) | S1PR1S1PR3S1PR4S1PR5S1PR2 | |
| Fty720-P SCHEMBL4267565 | 1.00 | S1PR1 (1.00) | S1PR1S1PR3S1PR4S1PR5S1PR2 | |
| Fty720-P SCHEMBL21225364 | 0.99 | S1PR1 (0.98) | S1PR1S1PR3S1PR4S1PR5S1PR2 | |
| SCHEMBL6510046 | 0.96 | S1PR1 (0.93) | S1PR1S1PR3S1PR4S1PR5S1PR2 | |
| SCHEMBL6502776 | 0.96 | S1PR1 (0.93) | S1PR1S1PR3S1PR4S1PR5S1PR2 | |
| SCHEMBL6502028 | 0.96 | S1PR1 (0.93) | S1PR1S1PR3S1PR4S1PR5S1PR2 | |
| SCHEMBL6529417 | 0.95 | S1PR1 (0.91) | S1PR1S1PR3S1PR4S1PR5S1PR2 | |
| Fty720P SCHEMBL30239630 | 0.95 | S1PR1 (0.91) | S1PR1S1PR3S1PR4S1PR5S1PR2 | |
| Fty720-P SCHEMBL13777289 | 0.92 | S1PR1 (0.84) | S1PR1S1PR3S1PR4S1PR5S1PR2 | |
| SCHEMBL6503014 | 0.92 | S1PR1 (0.84) | S1PR1S1PR3S1PR4S1PR5S1PR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 179 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250262171-A1 | DOSAGE REGIMEN FOR A S1P RECEPTOR AGONIST | NOVARTIS AG (CH) | 2025-08-21 | — | — | US | claimed |
| EP-4444865-A1 | METHODS AND COMPOSITIONS FOR IMPROVING ENDOTHELIAL CELL BARRIER | United Therapeutics Corporation (US) | 2024-10-16 | — | — | EP | claimed |
| WO-2024191589-A2 | PROBIOTIC AND CELLULAR GRAFT COMPOSITIONS FOR USES IN TISSUE REBUILDING | EMORY UNIVERSITY (US) | 2024-09-19 | — | — | WO | claimed |
| WO-2023107553-A1 | METHODS AND COMPOSITIONS FOR IMPROVING ENDOTHELIAL CELL BARRIER | UNITED THERAPEUTICS CORPORATION (US) | 2023-06-15 | — | — | WO | claimed |
| US-20230174947-A1 | METHODS AND COMPOSITIONS FOR IMPROVING ENDOTHELIAL CELL BARRIER | UNITED THERAPEUTICS CORPORATION (US) | 2023-06-08 | — | — | US | claimed |
| EP-4048247-A1 | TRANSDERMAL THERAPEUTIC SYSTEM FOR THE TRANSDERMAL ADMINISTRATION OF FINGOLIMOD | LTS Lohmann Therapie-Systeme AG (DE) | 2022-08-31 | — | — | EP | claimed |
| US-20150290145-A1 | Compositions and Methods for the Treatment of Parkinson's Disease | TEXAS TECH UNIVERSITY SYSTEM | 2015-10-15 | — | — | US | claimed |
| WO-2014063057-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE | TEXAS TECH UNIVERSITY SYSTEM (US) | 2014-04-24 | — | — | WO | claimed |
| US-20140107024-A1 | Treatment of Type 2 Diabetes With FTY720 | DIAPIN THERAPEUTICS LLC (US) | 2014-04-17 | — | — | US | claimed |
| US-8673918-B2 | Compositions comprising sphingosine 1 phosphate (S1P) receptor modulators | NOVARTIS AG (CH) | 2014-03-18 | — | — | US | claimed |
| EP-1660449-B1 | AMINOPROPANOL DERIVATIVES | NOVARTIS AG (CH) | 2009-11-18 | — | — | EP | claimed |
| US-20090156556-A1 | AMINOPROPANOL DERIVATIVES | ALBERT RAINER | 2009-06-18 | — | — | US | claimed |
| US-20060264403-A1 | Aminopropanol derivatives | NOVARTIS AG (CH) | 2006-11-23 | — | — | US | claimed |
| EP-1660449-A1 | AMINOPROPANOL DERIVATIVES | Novartis AG (CH) | 2006-05-31 | — | — | EP | claimed |
| EP-1315735-A4 | PHOSPHATE DERIVATIVES AS IMMUNOREGULATORY AGENTS | MERCK & CO INC (US) | 2005-04-06 | — | — | EP | claimed |
| WO-2005021503-A1 | AMINOPROPANOL DERIVATIVES | NOVARTIS AG (CH) | 2005-03-10 | — | — | WO | claimed |
| EP-1315735-A1 | PHOSPHATE DERIVATIVES AS IMMUNOREGULATORY AGENTS | Merck & Co., Inc. (US) | 2003-06-04 | — | — | EP | claimed |
| US-6437165-B1 | USEFUL FOR TREATING IMMUNE MEDIATED DISEASES AND CONDITIONS, SUCH AS BONE MARROW, ORGAN AND TISSUE TRANSPLANT REJECTION. | MERCK & CO., INC. | 2002-08-20 | — | — | US | claimed |
| US-20020091105-A1 | Phosphate derivatives as immunoregulatory agents | MERCK & CO., INC. | 2002-07-11 | — | — | US | claimed |
| WO-2002018395-A1 | PHOSPHATE DERIVATIVES AS IMMUNOREGULATORY AGENTS | MERCK & CO., INC. (US) | 2002-03-07 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020091105-A1 | Phosphate derivatives as immunoregulatory agents | ALPP, PPIP5K2, ALPI | S1PR1 382/4885S1PR3 520/4885S1PR4 499/4885 |
| US-20090156556-A1 | AMINOPROPANOL DERIVATIVES | ADRB1, ADRA1D, ADRA1A | S1PR1 3197/4885S1PR3 2743/4885S1PR4 3844/4885 |
| US-20250262171-A1 | DOSAGE REGIMEN FOR A S1P RECEPTOR AGONIST | S1PR1, S1PR4, S1PR2 | S1PR1 1/4885S1PR3 5/4885S1PR4 2/4885 |
| US-20150290145-A1 | Compositions and Methods for the Treatment of Parkinson's Disease | PARK7, SNCA, COMT | S1PR1 390/4885S1PR3 298/4885S1PR4 545/4885 |
| US-20060264403-A1 | Aminopropanol derivatives | ADRB1, ADRA1D, ADRA1A | S1PR1 3197/4885S1PR3 2743/4885S1PR4 3844/4885 |
| US-20140107024-A1 | Treatment of Type 2 Diabetes With FTY720 | SMPD2, SLC5A2, SPHK2 | S1PR1 39/4885S1PR3 37/4885S1PR4 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.